DRR168512
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.620
- PROTEIN_SECRETION+0.430
- INTERFERON_GAMMA_RESPONSE+0.390
- TGF_BETA_SIGNALING+0.340
- ANDROGEN_RESPONSE+0.180
- UV_RESPONSE_DN+0.150
- MYC_TARGETS_V1+0.100
- OXIDATIVE_PHOSPHORYLATION+0.100
- PI3K_AKT_MTOR_SIGNALING+0.080
- PEROXISOME+0.060
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
- MYOGENESIS-0.360
- MYC_TARGETS_V2-0.330
- ALLOGRAFT_REJECTION-0.320
- COAGULATION-0.290
- IL2_STAT5_SIGNALING-0.260
- WNT_BETA_CATENIN_SIGNALING-0.250
- BILE_ACID_METABOLISM-0.240
- E2F_TARGETS-0.240
- ANGIOGENESIS-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R324 | — | — | 0.812 |
| 2 | TCGA-E9-A1RD-01A-11R-A157-07 | — | B | 0.769 |
| 3 | SRR23303762 | — | — | 0.767 |
| 4 | R191 | — | — | 0.753 |
| 5 | R337 | — | — | 0.743 |
| 6 | SRR12202456 | — | — | 0.721 |
| 7 | SRR1516087 | — | — | 0.718 |
| 8 | SRR1797292 | — | cohortSC | 0.715 |
| 9 | TCGA-4Z-AA89-01A-11R-A39I-07 | — | — | 0.713 |
| 10 | ULC0409T_S43 | — | cohortA1 | 0.708 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.620 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.430 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.390 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.340 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.180 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.150 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.100 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.100 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.080 | Inavolisib | — uncovered |
| PEROXISOME | 0.060 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.050 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.010 | Inavolisib | — uncovered |